Delfi Diagnostics

Palo Alto, CA · Founded 2019 · Privately Held (backing)

Developer of a blood test system designed for the early detection of cancer. Delfi Diagnostics is based in Palo Alto, CA and was founded in 2019. Its last reported valuation was $725 million in Jun 2024. It has raised $466 million across 1 recorded round; the latest was a $34.3 million debt round in Dec 2025.

Last reported valuation
$725.0M
Oct 2026
Priced at
—
Total raised
$465.9M
Last round
Debt
Dec 2025
No prints on record

No secondary trades in Delfi Diagnostics shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.

Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Delfi Diagnostics with a free account
  • ·The complete investor list: 27 names
  • ·Watch Delfi Diagnostics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Where Delfi Diagnostics prices come from

Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Delfi Diagnostics stock.